Person:
ÇAKIR, FATMA BETÜL

Profile Picture
Status
Kurumdan Ayrılmıştır.
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
FATMA BETÜL
Last Name
ÇAKIR
Name
Email Address
Birth Date

Filters

2014 - 20162
Reset filters

Settings

Author: Cakir, FATMA BETÜL × Has files: true ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Desmoplastic infantile ganglioglioma: Report of an unusual case with a cranial defect.
    (2014-01-01) BASARAN, RUZİYE; Cakir, FATMA BETÜL; ISIK, N; SAV, A; ELMACI, I; BAŞARAN, RUZİYE; ÇAKIR, FATMA BETÜL
  • Thumbnail Image
    PublicationOpen Access
    Ceftriaxone-induced hemolytic anemia in a child successfully managed with intravenous immunoglobulin
    (2016-03-01) Vehapoglu, AYSEL; GOKNAR, Nilufer; TUNA, Rumeysa; Cakir, FATMA BETÜL; VEHAPOĞLU TÜRKMEN, AYSEL; ÇAKIR, FATMA BETÜL
    Drug-induced hemolytic anemia is an immune-mediated phenomenon that leads to the destruction of red blood cells. Here, we present a case of life-threatening ceftriaxone-induced hemolytic anemia (CIHA) in a previously healthy 3-year-old girl. We also reviewed the literature to summarize the clinical features and treatment of hemolytic anemia. Acute hemolysis is a rare side effect of ceftriaxone therapy associated with high mortality. Our patient had a sudden loss of consciousness with macroscopic hematuria and her hemoglobin dropped from 10.2 to 2.2 g/dl over 4 hours, indicating that the patient had life-threatening hemolysis after an intravascular dose of ceftriaxone who had previously been treated with ceftriaxone in intramuscular form for six days. CIHA is associated with a positive direct antiglobulin test, revealing the presence of IgG in all cases and C3d in most cases. Our patient's direct antiglobulin test was positive for IgG (3+) and for C3d (4+). The case was managed successfully with supportive measures and intravenous immunoglobulin therapy. Ceftriaxone is used very frequently in children; an early diagnosis and proper treatment of hemolytic anemia are essential to improve the patient outcome. The pathophysiological mechanism is the same as for non-drug autoimmune hemolytic anemia. However, there is still no consensus treatment for CIHA. Intravenous immunoglobulin can be used in clinical emergencies, such as our case, or in refractory cases.